SCHEMBL2276071

SCHEMBL2276071

O=C(Nc1cc(/C=C/c2ccc3c(c2)OCO3)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.58
CA2 P00918 2/20 0.58
CA9 Q16790 2/20 0.58
RAB9A P51151 8/20 0.56
NPC1 O15118 6/20 0.56
MAPT P10636 7/20 0.55
HTT P42858 1/20 0.55
PTGS2 P35354 1/20 0.54
PIM1 P11309 1/20 0.53
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
PKM P14618 4/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
HPGD P15428 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2C19 P33261 2/20 0.50
LMNA P02545 1/20 0.50
ALOX12 P18054 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2276083 1.00 CA12 (0.58) CA12CA2CA9RAB9ANPC1
SCHEMBL2274903 0.93 MAPT (0.57) CA12CA2CA9RAB9ANPC1
SCHEMBL2274887 0.93 MAPT (0.57) CA12CA2CA9RAB9ANPC1
SCHEMBL2274795 0.84 NPC1 (0.60) RAB9ANPC1MAPTHTTPTGS2
SCHEMBL21994188 0.84 RAB9A (0.61) RAB9ANPC1MAPTHTTPTGS2
SCHEMBL2276655 0.84 PKM (0.62) MAPTMEN1KMT2APKMTDP1
SCHEMBL2276651 0.84 PKM (0.62) MAPTMEN1KMT2APKMTDP1
SCHEMBL21933256 0.83 RAB9A (0.73) RAB9ANPC1MAPTHTTMEN1
SCHEMBL2270231 0.82 CASP3 (0.59) RAB9ANPC1MAPTPTGS2MEN1
SCHEMBL2275571 0.82 NPC1 (0.60) RAB9ANPC1MAPTPTGS2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 CA12 31/4885CA2 22/4885CA9 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.